M55 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Revenue Improvement And Reduced LossesHigher revenue and materially narrower losses indicate improving operating discipline or business mix. Although MacroGenics remains unprofitable, sustained progress toward breakeven could strengthen financial resilience if growth continues.
MGC026 Clinical AdvancementAdvancement into Stage 2 provides clinical validation for MGC026 and increases the pipeline’s long-term commercial potential. Further development could improve partnering prospects, though regulatory and efficacy risks remain.
Asset-light Operating ModelSelling manufacturing assets reduces operational intensity and shifts resources toward research and development. The supply agreement preserves production access while potentially improving capital efficiency and management focus on pipeline advancement.
Bears Say
Persistent Cash Burn And Funding DependenceNegative operating and free cash flow means the business is not yet self-funding. Continued cash consumption may require additional financing or partnering proceeds, creating dilution, execution, and funding risks over the medium term.
Unprofitable Operating ModelDespite improved margins, negative EBIT and EBITDA show that core operations have not reached sustainable profitability. Ongoing losses limit financial flexibility and make results dependent on pipeline progress, milestones, or other external funding.
Early-stage Clinical And Partnership DependenceThe company’s value creation remains tied to early clinical programs and collaboration economics rather than a broad commercial product base. Delays, trial failures, or weak partner execution could materially reduce future revenue opportunities.
MacroGenics News
M55 FAQ
What was MacroGenics’s price range in the past 12 months?
Currently, no data Available
What is MacroGenics’s market cap?
MacroGenics’s market cap is CHF207.01M.
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is Nov 04, 2026 which is in 68 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Aug 13, 2026. The company reported CHF0.252 earnings per share for the quarter, beating the consensus estimate of -CHF0.063 by CHF0.315.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -0.24.
How many shares outstanding does MacroGenics have?
MacroGenics has 63,700,188 shares outstanding.
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of CHF0.252 in its last earnings report, beating expectations of -CHF0.063. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of MacroGenics?
Currently, no hedge funds are holding shares in CH:M55
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MacroGenics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF5.62 (― Upside)
CHF5.62 (― Upside)
Blogger Sentiment
Neutral
CH:M55 Sentiment 75%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
107.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
40.74%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.